Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06278285

Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery

Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Nice - Hôpital de l'Archet

Nice, Alpes-maritimes, 06200, France

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18 years of age.
  • Patient able to read and understand the information/consent leaflet.
  • Patient with BMI > 35 with at least one comorbidity. Or BMI > 40
  • Indication for digestive surgery validated in a multidisciplinary consultation meeting and prior agreement accepted by the CPAM.
  • Membership of a social security scheme
  • Patient's signed informed consent
  • For subjects in the GLP-1 analogue group: GLP-1 analogue taken for at least 3 months.
  • For non-GLP-1 analogue group: never taken GLP-1 analogues.

Exclusion criteria

  • Pregnant or breast-feeding women.
  • Vulnerable patients (under guardianship)
  • Patients deprived of liberty

Treatment and study plan

Blood GLP1

Other

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with anti-GLP-1 analogues

Blood No treated GLP1

Other

On the day of surgery, the surgeon will remove visceral adipose tissue (1 cm3) from the operative waste. The adipose tissue is separated into 2 samples, one frozen in nitrogen, the other embedded in formalin. The samples are then sent to the Institut de Biologie de Valrose (iBV) to assess any differences between the two groups of patients (patients treated with patients not treated with anti-GLP-1 analogues) and the presence of fibrosis.

Primary outcomes

  1. Rate of oxytocin

    Time frame: one time (before surgery)

    show that subjects treated with a GLP-1 agonist have a significant change in oxytocin levels compared with subjects not treated with a GLP-1 agonist.

Secondary outcomes

  1. Fibrosis rate

    Time frame: At surgery

    compare adipose tissue caracteristics between patients treated by analog GLP1 and not treated by analog GLP1

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Acronym: Maigrir_OT

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Feb 26, 2024
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.